COMMUNIQUÉS West-GlobeNewswire

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
02/01/2019
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering [...]
gammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)
02/01/2019
BASKING RIDGE, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced its non-invasive vagus nerve stimulation (nVNS) therapy, [...]
Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
02/01/2019
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO, Jan. [...]
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
ALPHARETTA, Ga., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the 37th Annual J.P [...]
Tauriga Sciences, Inc. Enters into Manufacturing Agreement for the Production of its Cannabis/CBD Infused Chewing Gum Product
02/01/2019
NEW YORK, NY, Jan. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of [...]
CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
NEWARK, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]
Inovalon to Present at 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
BOWIE, Md., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading technology company providing advanced, cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D [...]
Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
02/01/2019
PHILADELPHIA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that [...]
VitalHub Announces Licensing of B Care EHR to the Toronto Grace Health Centre to Replace Multiple Legacy Systems and Provide an Integrated Hospital Information System
02/01/2019
TORONTO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSXV: VHI) is pleased to announce the sale of B Care to The Salvation Army Toronto Grace Health Centre (“TGHC”). TGHC sought a comprehensive, [...]
Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
02/01/2019
SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestone Advancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions rigosertib in an [...]
Nephros Announces Acquisition of Biocon
02/01/2019
Adds Growing Water Filtration Business in Food Service, Hospitality, and Industrial Markets Expands Water Filter Product Portfolio SOUTH ORANGE, NJ, Jan. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. ( [...]
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that [...]
Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference
02/01/2019
SAN DIEGO and TORONTO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of [...]
Resonant Inc. Enters 2019 with Over 20 Devices Accepted by Customers
02/01/2019
Includes first 5G device Doubles the number of devices accepted by customers announced at the beginning of 2018 GOLETA, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming [...]
Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex™ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy
02/01/2019
CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019 NEW HAVEN, Conn., [...]
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018
02/01/2019
Full-Year 2018 Revenue Expected to be Between $113 Million and $115 Million Anticipated Revenues Exceed Current Revenue Guidance of $102 Million to $108 Million Expected Full-Year 2018 Total Revenue Would Represent [...]
Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
02/01/2019
- 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the [...]
Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
02/01/2019
- Trial continues as planned with enrollment target of 350 patients - - Top-line data readout expected in the first half of 2019 - STAMFORD, Conn., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA [...]

Pages